

8. LITERATURVERZEICHNIS

Aarsland, D., Tandberg, E., Larsen, J. P. und Cummings, J. L. (1996)

Frequency of dementia in Parkinson disease.
Arch Neurol **53** (6), 538-542.

Abercrombie, E. D., Keefe, K. A., DiFrischia, D. S. und Zigmond, M. J. (1989)

Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex.
J Neurochem **52** (5), 1655-1658.

Abercrombie, M. (1946)

Estimation of nuclear population from microtome sections.
Anat Rec **94** 239-247.

Adam-Vizi, V. (2005)

Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources.
Antioxid Redox Signal **7** (9-10), 1140-1149.

Adams, J. D., Jr., Klaidman, L. K. und Ribeiro, P. (1997)

Tyrosine hydroxylase: mechanisms of oxygen radical formation.
Redox Rep **3** (5-6), 273-279.

Aizman, O., Brismar, H., Uhlen, P., Zettergren, E., Levey, A. I., Forsberg, H., Greengard, P. und Aperia, A. (2000)

Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons.
Nat Neurosci **3** (3), 226-230.

Al-Fayez, M., Russell, D., Wayne Davies, R., Shiels, P. G., Baker, P. J. und Payne, A. P. (2005)

Deficits in the mid-brain raphe nuclei and striatum of the AS/AGU rat, a protein kinase C-gamma mutant.
Eur J Neurosci **22** (11), 2792-2798.

Alam, M. und Schmidt, W. J. (2002)

Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.
Behav Brain Res **136** (1), 317-324.

Alam, M. und Schmidt, W. J. (2004a)

L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Behav Brain Res **153** (2), 439-446.

Alam, M. und Schmidt, W. J. (2004b)

Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson's disease.
Physiol Behav **83** (3), 395-400.

Alexander, G. E., Crutcher, M. D. und DeLong, M. R. (1990)

Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions.
Prog Brain Res **85** 119-146.

Allen, K. L., Almeida, A., Bates, T. E. und Clark, J. B. (1995)

Changes of respiratory chain activity in mitochondrial and synaptosomal fractions isolated from the gerbil brain after graded ischaemia.
J Neurochem **64** (5), 2222-2229.

Altman, J. (1992)

Programmed cell death: the paths to suicide.
Trends Neurosci **15** (8), 278-280.

Andringa, G., van Oosten, R. V., Unger, W., Hafmans, T. G., Veening, J., Stoof, J. C. und Cools, A. R. (2000)

Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.
Eur J Neurosci **12** (8), 3033-3043.

Antonini, A., Vontobel, P., Psylla, M., Gunther, I., Maguire, P. R., Missimer, J. und Leenders, K. L. (1995)

Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Arch Neurol **52** (12), 1183-1190.

- Arikan, R., Blake, N. M., Erinjeri, J. P., Woolsey, T. A., Giraud, L. und Highstein, S. M. (2002)**
A method to measure the effective spread of focally injected muscimol into the central nervous system with electrophysiology and light microscopy.
J Neurosci Methods **118** (1), 51-57.
- Bailey, K. R., Rustay, N. R. und Crawley, J. N. (2006)**
Behavioral phenotyping of transgenic and knockout mice: practical concerns and potential pitfalls.
Ilar J **47** (2), 124-131.
- Baulieu, E. E. (1998)**
Neurosteroids: a novel function of the brain.
Psychoneuroendocrinology **23** (8), 963-987.
- Beal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, E., Srivastava, R., Rosen, B. R. und Hyman, B. T. (1993)**
Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.
J Neurosci **13** (10), 4181-4192.
- Ben-Nathan, D., Lachmi, B., Lustig, S. und Feuerstein, G. (1991)**
Protection by dehydroepiandrosterone in mice infected with viral encephalitis.
Arch Virol **120** (3-4), 263-271.
- Ben-Shachar, D. und Youdim, M. B. (1991)**
Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats.
J Neurochem **57** (6), 2133-2135.
- Benabid, A. L., Pollak, P., Gross, C., Hoffmann, D., Benazzouz, A., Gao, D. M., Laurent, A., Gentil, M. und Perret, J. (1994)**
Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease.
Stereotact Funct Neurosurg **62** (1-4), 76-84.
- Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. und Seitelberger, F. (1973)**
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
J Neurol Sci **20** (4), 415-455.
- Betarbet, R., Canet-Aviles, R. M., Sherer, R., Seo, B. B., Klinefelter, G., Cookson, M. R. und Greenamyre, J. T. (2006)**
Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.
Neurobiol Dis **22** (2), 404-420.
- Betarbet, R., Sherer, T. B., Di Monte, D. A. und Greenamyre, J. T. (2002a)**
Mechanistic approaches to Parkinson's disease pathogenesis.
Brain Pathol **12** (4), 499-510.
- Betarbet, R., Sherer, T. B. und Greenamyre, J. T. (2002b)**
Animal models of Parkinson's disease.
Bioessays **24** (4), 308-318.
- Betarbet, R., Sherer, T. B. und Greenamyre, J. T. (2005)**
Ubiquitin-proteasome system and Parkinson's diseases.
Exp Neurol **191** Suppl 1 S17-27.
- Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V. und Greenamyre, J. T. (2000)**
Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
Nat Neurosci **3** (12), 1301-1306.
- Birkmayer, W. und Hornykiewicz, O. (2001)**
The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.
Wien Klin Wochenschr **113** (22), 851-854.
- Birkmayer, W., Riederer, P., Youdim, M. B. und Linauer, W. (1975)**
The potentiation of the anti akinesic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.
J Neural Transm **36** (3-4), 303-326.
- Bjorklund, A., Dunnett, S. B., Brundin, P., Levivier, M., Peschanski, M., Studer, L. und Barker, R. (2003)**
Neural transplantation for the treatment of Parkinson's disease.
Lancet Neurol **2** (7), 437-445.

- Blanchard, V., Chritin, M., Vyas, S., Savasta, M., Agid, Y., Javoy-Agid, F. und Raisman-Vozari, R. (1995)**
Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain.
J Neurochem **64** (4), 1669-1679.
- Blandini, F. und Greenamyre, J. T. (1999)**
Protective and symptomatic strategies for therapy of Parkinson's disease.
Drugs Today (Barc) **35** (6), 473-483.
- Blandini, F., Nappi, G., Tassorelli, C. und Martignoni, E. (2000)**
Functional changes of the basal ganglia circuitry in Parkinson's disease.
Prog Neurobiol **62** (1), 63-88.
- Bolivar, V. J., Caldarone, B. J., Reilly, A. A. und Flaherty, L. (2000)**
Habituation of activity in an open field: A survey of inbred strains and F1 hybrids.
Behav Genet **30** (4), 285-293.
- Bonifati, V., Oostra, B. A. und Heutink, P. (2004)**
Unraveling the pathogenesis of Parkinson's disease--the contribution of monogenic forms.
Cell Mol Life Sci **61** (14), 1729-1750.
- Bove, J., Prou, D., Perier, C. und Przedborski, S. (2005)**
Toxin-induced models of Parkinson's disease.
NeuroRx **2** (3), 484-494.
- Bowling, A. C. und Beal, M. F. (1995)**
Bioenergetic and oxidative stress in neurodegenerative diseases.
Life Sci **56** (14), 1151-1171.
- Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D. und Rub, U. (2002)**
Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).
J Neurol **249** Suppl 3 III/1-5.
- Brouillet, E., Hyman, B. T., Jenkins, B. G., Henshaw, D. R., Sodhi, P., Rosen, B. R. und Beal, M. F. (1994)**
Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism.
Exp Neurol **129** (2), 175-182.
- Brown, R. C., Lockwood, A. H. und Sonawane, B. R. (2005)**
Neurodegenerative diseases: an overview of environmental risk factors.
Environ Health Perspect **113** (9), 1250-1256.
- Buccafusco, J. J. (2001)**
Methods of Behavior Analysis in Neuroscience.
Boca Raton, Florida, USA, CRC Press LLC,
- Caboni, P., Sherer, T. B., Zhang, N., Taylor, G., Na, H. M., Greenamyre, J. T. und Casida, J. E. (2004)**
Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
Chem Res Toxicol **17** (11), 1540-1548.
- Carlsson, A., Lindqvist, M. und Magnusson, T. (1957)**
3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.
Nature **180** (4596), 1200.
- Casarejos, M. J., Menendez, J., Solano, R. M., Garcia de Yebenes, J. und Mena, M. A. (2006)**
Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline.
J Neurochem **97** (4), 934-946.
- Cass, W. A., Harned, M. E. und Bailey, S. L. (2002)**
Enhanced effects of 6-hydroxydopamine on evoked overflow of striatal dopamine in aged rats.
Brain Res **938** (1-2), 29-37.
- Chia, L. G., Ni, D. R., Cheng, F. C., Ho, Y. P. und Kuo, J. S. (1999)**
Intra-striatal injection of 5,7-dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice.
Neurochem Res **24** (6), 719-722.

Chinopoulos, C. und Adam-Vizi, V. (2006)

Calcium, mitochondria and oxidative stress in neuronal pathology. Novel aspects of an enduring theme. *Febs J* **273** (3), 433-450.

Chung, K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Ross, C. A., Dawson, V. L. und Dawson, T. M. (2001)

Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. *Nat Med* **7** (10), 1144-1150.

Cicchetti, F., Lapointe, N., Roberge-Tremblay, A., Saint-Pierre, M., Jimenez, L., Ficke, B. W. und Gross, R. E. (2005)

Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. *Neurobiol Dis* **20** (2), 360-371.

Cleeter, M. W., Cooper, J. M. und Schapira, A. H. (1992)

Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. *J Neurochem* **58** (2), 786-789.

Coggeshall, R. E. und Lekan, H. A. (1996)

Methods for determining numbers of cells and synapses: a case for more uniform standards of review. *J Comp Neurol* **364** (1), 6-15.

Colotla, V. A., Flores, E., Ocos, A., Meneses, A. und Tapia, R. (1990)

Effects of MPTP on locomotor activity in mice. *Neurotoxicol Teratol* **12** (4), 405-407.

Compagnone, N. A. und Mellon, S. H. (2000)

Neurosteroids: biosynthesis and function of these novel neuromodulators. *Front Neuroendocrinol* **21** (1), 1-56.

Conley, S. C. und Kirchner, J. T. (1999)

Parkinson's disease--the shaking palsy. Underlying factors, diagnostic considerations, and clinical course. *Postgrad Med* **106** (1), 39-42, 45-36, 49-50 passim.

Coons, A. H. und Kaplan, M. H. (1950)

Localization of antigen in tissue cells; improvements in a method for the detection of antigen by means of fluorescent antibody. *J Exp Med* **91** (1), 1-13.

Corasaniti, M. T., Strongoli, M. C., Rotiroti, D., Bagetta, G. und Nistico, G. (1998)

Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. *Pharmacol Toxicol* **83** (1), 1-7.

Coyle, J. T. und Puttfarcken, P. (1993)

Oxidative stress, glutamate, and neurodegenerative disorders. *Science* **262** (5134), 689-695.

Crawley, J. N. (1999a)

Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. *Brain Res* **835** (1), 18-26.

Crawley, J. N. (1999b)

What's Wrong With My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice. New York, Wiley-Liss.

Cross, A. K. und Woodroffe, M. N. (2001)

Immunoregulation of microglial functional properties. *Microsc Res Tech* **54** (1), 10-17.

Crossman, A. R. (1989)

Neural mechanisms in disorders of movement. *Comp Biochem Physiol A* **93** (1), 141-149.

Cunningham, L. A. und Su, C. (2002)

Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. *Exp Neurol* **174** (2), 230-242.

Curzon, G. (1977)

The biochemistry of the basal ganglia and Parkinson's disease. *Postgrad Med J* **53** (626), 719-725.

- D'Astous, M., Morissette, M., Tanguay, B., Callier, S. und Di Paolo, T. (2003)**
Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
Synapse **47** (1), 10-14.
- Dahme, E. und Weiss, E. (1999)**
Grundriss der speziellen pathologischen Anatomie der Haustiere. Enke-Verlag.
- Damier, P., Hirsch, E. C., Agid, Y. und Graybiel, A. M. (1999)**
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Brain **122** (Pt 8) 1437-1448.
- Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M. und Kopin, I. J. (1979)**
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.
Psychiatry Res **1** (3), 249-254.
- de Rijk, M. C., Launer, L. J., Berger, K., Breteler, J. F., Martinez-Lage, J., Trenkwalder, C. und Hofman, A. (2000)**
Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.
Neurology **54** (11 Suppl 5), S21-23.
- Dekundy, A., Pietraszek, M., Schaefer, D., Cenci, M. A. und Danysz, W. (2006)**
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Brain Res Bull **69** (3), 318-326.
- Del Dotto, P., Pavese, N., Gambaccini, G., Bernardini, S., Metman, L. V., Chase, T. N. und Bonuccelli, U. (2001)**
Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Mov Disord **16** (3), 515-520.
- Deumens, R., Blokland, A. und Prickaerts, J. (2002)**
Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
Exp Neurol **175** (2), 303-317.
- Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P. und Marsden, C. D. (1987)**
Increased nigral iron content in postmortem parkinsonian brain.
Lancet **2** (8569), 1219-1220.
- di Michele, F., Longone, P., Romeo, E., Lucchetti, L., Pierantozzi, M., Bassi, A., Bernardi, G. und Stanzione, P. (2003)**
Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease.
Neurol Sci **24** (3), 172-173.
- Di Monte, D., Sandy, M. S., Ekstrom, G. und Smith, M. T. (1986)**
Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity.
Biochem Biophys Res Commun **137** (1), 303-309.
- Di Monte, D. A. (2003)**
The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?
Lancet Neurol **2** (9), 531-538.
- Dibble, L. E., Hale, T. F., Marcus, R. L., Droge, J., Gerber, J. P. und Lastayo, P. C. (2006)**
High-intensity resistance training amplifies muscle hypertrophy and functional gains in persons with Parkinson's disease.
Mov Disord.
- DiDonato, S., Zeviani, M., Giovannini, P., Savarese, N., Rimoldi, M., Mariotti, C., Girotti, F. und Caraceni, T. (1993)**
Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients.
Neurology **43** (11), 2262-2268.
- Divac, I., Fonnum, F. und Storm-Mathisen, J. (1977)**
High affinity uptake of glutamate in terminals of corticostriatal axons.
Nature **266** (5600), 377-378.
- Dluzen, D. E. und Kreutzberg, J. D. (1993)**
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse.
Brain Res **609** (1-2), 98-102.
- Duda, J. E., Giasson, B. I., Mabon, M. E., Miller, D. C., Golbe, L. I., Lee, V. M. und Trojanowski, J. Q. (2002)**
Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.
Acta Neuropathol (Berl) **104** (1), 7-11.

Dunnett, S. B. und Bjorklund, A. (1999)

Prospects for new restorative and neuroprotective treatments in Parkinson's disease.
Nature **399** (6738 Suppl), A32-39.

Ebadi, M., Brown-Borg, H., El Refaey, H., Singh, B. B., Garrett, S., Shavali, S. und Sharma, S. K. (2005)

Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease.
Brain Res Mol Brain Res **134** (1), 67-75.

Ehrhart, J. und Zeevalk, G. D. (2003)

Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures.
J Neurochem **86** (6), 1487-1497.

Ellenbroek, B. A., Peeters, B. W., Honig, W. M. und Cools, A. R. (1987)

The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs.
Psychopharmacology (Berl) **93** (3), 343-348.

Ellenhorn, M. J. und Barceloux, D. G. (1988)

Medical toxicology, diagnosis and the treatment of human poisoning.
New York, Elsevier, 1512.

Farrer, M. J. (2006)

Genetics of Parkinson disease: paradigm shifts and future prospects.
Nat Rev Genet **7** (4), 306-318.

Fasano, M., Bergamasco, B. und Lopiano, L. (2006)

Modifications of the iron-neuromelanin system in Parkinson's disease.
J Neurochem **96** (4), 909-916.

Faull, R. L. und Laverly, R. (1969)

Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra.
Exp Neurol **23** (3), 332-340.

Fearnley, J. M. und Lees, A. J. (1991)

Ageing and Parkinson's disease: substantia nigra regional selectivity.
Brain **114** (Pt 5) 2283-2301.

Fenelon, G., Mahieux, F., Huon, R. und Ziegler, M. (2000)

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.
Brain **123** (Pt 4) 733-745.

Fernandez, A., de Ceballos, M. L., Rose, S., Jenner, P. und Marsden, C. D. (1996)

Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.
Brain **119** (Pt 3) 823-830.

Ferrante, R. J., Schulz, J. B., Kowall, N. W. und Beal, M. F. (1997)

Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra.
Brain Res **753** (1), 157-162.

Fleming, S. M., Fernagut, P. O. und Chesselet, M. F. (2005)

Genetic mouse models of parkinsonism: strengths and limitations.
NeuroRx **2** (3), 495-503.

Fleming, S. M., Zhu, C., Fernagut, P. O., Mehta, A., DiCarlo, C. D., Seaman, R. L. und Chesselet, M. F. (2004)

Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
Exp Neurol **187** (2), 418-429.

Fontaine, E., Eriksson, O., Ichas, F. und Bernardi, P. (1998)

Regulation of the permeability transition pore in skeletal muscle mitochondria. Modulation By electron flow through the respiratory chain complex i.
J Biol Chem **273** (20), 12662-12668.

Gandhi, S. und Wood, N. W. (2005)

Molecular pathogenesis of Parkinson's disease.
Hum Mol Genet **14** (18), 2749-2755.

Gasser, T. (2001)

Genetics of Parkinson's disease.
J Neurol **248** (10), 833-840.

Gerlach, M., Reichmann, H., Riederer, P. (2003)

Die Parkinson-Krankheit.
Wien, Springer-Verlag.

Gerlach, M. und Riederer, P. (1996)

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.
J Neural Transm **103** (8-9), 987-1041.

Gibb, W. R. und Lees, A. J. (1991)

Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease.
J Neurol Neurosurg Psychiatry **54** (5), 388-396.

Giovanni, A., Sonsalla, P. K. und Heikkila, R. E. (1994)

Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
J Pharmacol Exp Ther **270** (3), 1008-1014.

Glinka, Y. Y. und Youdim, M. B. (1995)

Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine.
Eur J Pharmacol **292** (3-4), 329-332.

Gonzalez-Hernandez, T. und Rodriguez, M. (2000)

Compartmental organization and chemical profile of dopaminergic and GABAergic neurons in the substantia nigra of the rat.
J Comp Neurol **421** (1), 107-135.

Gorell, J. M., Johnson, C. C., Rybicki, B. A., Kortsha, G. X., Brown, G. G. und Richardson, R. J. (1999)

Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease.
Neurotoxicology **20** (2-3), 239-247.

Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L. und Richardson, R. J. (1998)

The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living.
Neurology **50** (5), 1346-1350.

Gossel, M., Schmidt, W. J., Loscher, W., Zajaczkowski, W. und Danysz, W. (1995)

Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats.
J Neural Transm Park Dis Dement Sect **10** (1), 27-39.

Graham, D. G. (1978)

Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.
Mol Pharmacol **14** (4), 633-643.

Greenamyre, J. T., MacKenzie, G., Garcia-Osuna, M. und Betarbet, R. (1999)

A Novel Model of Slowly Progressive Parkinson's Disease: Chronic Pesticide Exposure.
Movement Disorders **Vol. 14** (No. 5), 900.

Group, T. P. S. (1993)

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
N Engl J Med **328** (3), 176-183.

Guenebaut, V., Vincentelli, R., Mills, D., Weiss, H. und Leonard, K. R. (1997)

Three-dimensional structure of NADH-dehydrogenase from *Neurospora crassa* by electron microscopy and conical tilt reconstruction.
J Mol Biol **265** (4), 409-418.

Hadjiconstantinou, M. und Neff, N. H. (1990)

Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment.
Eur J Pharmacol **181** (1-2), 137-139.

Hahn, J., Kullmann, P. H., Horn, J. P. und Levitan, E. S. (2006)

D2 autoreceptors chronically enhance dopamine neuron pacemaker activity.
J Neurosci **26** (19), 5240-5247.

Halliwell, B. (1992)

Reactive oxygen species and the central nervous system.
J Neurochem **59** (5), 1609-1623.

Hamann, M., Meisler, M. H. und Richter, A. (2003)

Motor disturbances in mice with deficiency of the sodium channel gene Scn8a show features of human dystonia.
Exp Neurol **184** (2), 830-838.

Hamann, M. und Richter, A. (2002)

Effects of striatal injections of GABA(A) receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia.
Eur J Pharmacol **443** (1-3), 59-70.

Hardingham, G. E. und Bading, H. (2003)

The Yin and Yang of NMDA receptor signalling.
Trends Neurosci **26** (2), 81-89.

Hatefi, Y. (1985)

The mitochondrial electron transport and oxidative phosphorylation system.
Annu Rev Biochem **54** 1015-1069.

Hattori, N., Kobayashi, H., Sasaki-Hatano, Y., Sato, K. und Mizuno, Y. (2003)

Familial Parkinson's disease: a hint to elucidate the mechanisms of nigral degeneration.
J Neurol **250** Suppl 3 III2-10.

He, Y., Appel, S. und Le, W. (2001)

Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum.
Brain Res **909** (1-2), 187-193.

Hedreen, J. C. und DeLong, M. R. (1991)

Organization of striatopallidal, striatonigral, and nigrostriatal projections in the macaque.
J Comp Neurol **304** (4), 569-595.

Heikkila, R. E. und Cohen, G. (1972)

In vivo generation of hydrogen peroxide from 6-hydroxydopamine.
Experientia **28** (10), 1197-1198.

Hirsch, E. C., Brandel, J. P., Galle, P., Javoy-Agid, F. und Agid, Y. (1991)

Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
J Neurochem **56** (2), 446-451.

Hirsch, E. C., Orioux, G., Muriel, M. P., Francois, C. und Feger, J. (2003)

Nondopaminergic neurons in Parkinson's disease.
Adv Neurol **91** 29-37.

Hisata, J. S. (2002)

Lake and Stream Rehabilitation: Rotenone Use and Health Risks.
In Wildlife, W. S. D. o. F. a. (ed.) Final Supplemental Environmental Impact Statement.
Washington.

Ho, A. und Blum, M. (1998)

Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease.
J Neurosci **18** (15), 5614-5629.

Höglinger, G. U., Feger, J., Prigent, A., Michel, P. P., Parain, K., Ruberg, M., Oertel, W. H. und Hirsch, E. C. (2003)

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats.
J Neurochem **84** (3), 491-502.

Holdorff, B. (2002)

Friedrich Heinrich Lewy (1885-1950) and his work.
J Hist Neurosci **11** (1), 19-28.

Hornykiewicz, O. (1963)

[The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease.].
Wien Klin Wochenschr **75** 309-312.

Hornykiewicz, O. (1982)

Imbalance of brain monoamines and clinical disorders.
Prog Brain Res **55** 419-429.

Hornykiewicz, O. und Kish, S. J. (1987)

Biochemical pathophysiology of Parkinson's disease.
Adv Neurol **45** 19-34.

Hoshi, E., Tremblay, L., Feger, J., Carras, P. L. und Strick, P. L. (2005)

The cerebellum communicates with the basal ganglia.
Nat Neurosci **8** (11), 1491-1493.

Hutchison, W. D., Lozano, A. M., Tasker, R. R., Lang, A. E. und Dostrovsky, J. O. (1997)

Identification and characterization of neurons with tremor-frequency activity in human globus pallidus.
Exp Brain Res **113** (3), 557-563.

Hutson, P. H. und Curzon, G. (1983)

Monitoring in vivo of transmitter metabolism by electrochemical methods.
Biochem J **211** (1), 1-12.

Ichitani, Y., Okamura, H., Nakahara, D., Nagatsu, I. und Ibata, Y. (1994)

Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra.
Exp Neurol **130** (2), 269-278.

Iivicky, J. und Casida, J. E. (1969)

Uncoupling action of 2,4-dinitrophenols, 2-trifluoromethylbenzimidazoles and certain other pesticide chemicals upon mitochondria from different sources and its relation to toxicity.
Biochem Pharmacol **18** (6), 1389-1401.

Ingram, D. K., London, E. D., Waller, S. B. und Reynolds, M. A. (1983)

Age-dependent correlation of motor performance with neurotransmitter synthetic enzyme activities in mice.
Behav Neural Biol **39** (2), 284-298.

Ingram, D. K., Weindruch, R., Spangler, E. L., Freeman, J. R. und Walford, R. L. (1987)

Dietary restriction benefits learning and motor performance of aged mice.
J Gerontol **42** (1), 78-81.

Irwin, I., Finnegan, K. T., Delanney, L. E., Di Monte, D. und Langston, J. W. (1992)

The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment.
Brain Res **572** (1-2), 224-231.

Irwin, I., Ricaurte, G. A., DeLanney, L. E. und Langston, J. W. (1988)

The sensitivity of nigrostriatal dopamine neurons to MPP+ does not increase with age.
Neurosci Lett **87** (1-2), 51-56.

Iversen, L. (2006)

Neurotransmitter transporters and their impact on the development of psychopharmacology.
Br J Pharmacol **147** Suppl 1 S82-88.

Jackson-Lewis, V., Jakowec, M., Burke, R. E. und Przedborski, S. (1995)

Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Neurodegeneration **4** (3), 257-269.

Jakowec, M. W., Nixon, K., Hogg, E., McNeill, T. und Petzinger, G. M. (2004)

Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
J Neurosci Res **76** (4), 539-550.

Jakowec, M. W. und Petzinger, G. M. (2004)

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
Comp Med **54** (5), 497-513.

Javoy-Agid, F., Ruberg, M., Taquet, H., Bokobza, B., N'Guyen-Legros, J., Alvarez, C., Gray, F. und et al. (1984)

Biochemical neuropathology of Parkinson's disease.
Adv Neurol **40** 189-198.

Jazwinski, S. M. (2000)

Aging and longevity genes.
Acta Biochim Pol **47** (2), 269-279.

Jellinger, K. A. (1991)

Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway.
Mol Chem Neuropathol **14** (3), 153-197.

Jellinger, K. A. (1999)

Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
J Neural Transm Suppl **56** 1-29.

Jenner, P. (1998)

Oxidative mechanisms in nigral cell death in Parkinson's disease.
Mov Disord **13 Suppl 1** 24-34.

Joel, D. und Weiner, I. (2000)

The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum.
Neuroscience **96** (3), 451-474.

Kahle, P. J., Haass, C., Kretschmar, H. A. und Neumann, M. (2002)

Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases.
J Neurochem **82** (3), 449-457.

Kamel, F., Moreno, T., Rowland, A. S., Stallone, L., Ramirez-Garnica, G. und Sandler, D. P. (2001)

Recruiting a community sample in collaboration with farmworkers.
Environ Health Perspect **109 Suppl 3** 457-459.

Kandel, E. R., Schwartz, J. H., Jessel, T. M. (1995)

Neurowissenschaften.
Heidelberg, Spektrum, Akad. Verlag.

Katzenschlager, R., Sampaio, C., Costa, J. und Lees, A. (2003)

Anticholinergics for symptomatic management of Parkinson's disease.
Cochrane Database Syst Rev (2), CD003735.

Kim, S. T., Choi, J. H., Kim, D. und Hwang, O. (2006)

Increases in TH immunoreactivity, neuromelanin and degeneration in the substantia nigra of middle aged mice.
Neurosci Lett **396** (3), 263-268.

Kirik, D., Rosenblad, C. und Bjorklund, A. (1998)

Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.
Exp Neurol **152** (2), 259-277.

Kish, S. J., Shannak, K., Rajput, A., Deck, J. H. und Hornykiewicz, O. (1992)

Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease.
J Neurochem **58** (2), 642-648.

Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Minoshima, S., Yokochi, M., Mizuno, Y. und Shimizu, N. (1998)

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
Nature **392** (6676), 605-608.

Kostrzewa, R. M. und Jacobowitz, D. M. (1974)

Pharmacological actions of 6-hydroxydopamine.
Pharmacol Rev **26** (3), 199-288.

Kweon, G. R., Marks, J. D., Krencik, R., Leung, E. H., Schumacker, P. T., Hyland, K. und Kang, U. J. (2004)

Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells.
J Biol Chem **279** (50), 51783-51792.

Lang, A. E. und Lozano, A. M. (1998)

Parkinson's disease. First of two parts.
N Engl J Med **339** (15), 1044-1053.

Langston, J. W., Ballard, P., Tetrud, J. W. und Irwin, I. (1983)

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
Science **219** (4587), 979-980.

Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A. und Karluk, D. (1999)

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure.
Ann Neurol **46** (4), 598-605.

Lapointe, N., St-Hilaire, M., Martinoli, M. G., Blanchet, J., Gould, P., Rouillard, C. und Cicchetti, F. (2004)

Rotenone induces non-specific central nervous system and systemic toxicity.
Faseb J **18** (6), 717-719.

Le Couteur, D. G., McLean, A. J., Taylor, M. C., Woodham, B. L. und Board, P. G. (1999)

Pesticides and Parkinson's disease.
Biomed Pharmacother **53** (3), 122-130.

Le Couteur, D. G., Muller, M., Yang, M. C., Mellick, G. D. und McLean, A. J. (2002)

Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease.
Rev Environ Health **17** (1), 51-64.

Le Moal, M. und Simon, H. (1991)

Mesocorticolimbic dopaminergic network: functional and regulatory roles.
Physiol Rev **71** (1), 155-234.

Le, W. und Appel, S. H. (2004)

Mutant genes responsible for Parkinson's disease.
Curr Opin Pharmacol **4** (1), 79-84.

Lee, C. S., Sauer, H. und Bjorklund, A. (1996)

Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat.
Neuroscience **72** (3), 641-653.

Leist, M., Single, B., Naumann, H., Fava, E., Simon, B., Kuhnle, S. und Nicotera, P. (1999)

Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis.
Exp Cell Res **249** (2), 396-403.

Levey, A. I., Hersch, S. M., Rye, D. B., Sunahara, R. K., Maggio, R., Brann, M. R., Ciliax, B. J. und et al. (1993)

Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies.
Proc Natl Acad Sci U S A **90** (19), 8861-8865.

Li, N., Ragheb, K., Lawler, G., Sturgis, J., Rajwa, B., Melendez, J. A. und Robinson, J. P. (2003)

Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.
J Biol Chem **278** (10), 8516-8525.

Lindner, M. D., Cain, C. K., Plone, M. A., Frydel, B. R., Blaney, T. J., Emerich, D. F. und Hoane, M. R. (1999)

Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
Behav Brain Res **102** (1-2), 1-16.

Link, C. D. (2001)

Transgenic invertebrate models of age-associated neurodegenerative diseases.
Mech Ageing Dev **122** (14), 1639-1649.

Lohman, R. J., Liu, L., Morris, M. und O'Brien, T. J. (2005)

Validation of a method for localised microinjection of drugs into thalamic subregions in rats for epilepsy pharmacological studies.
J Neurosci Methods **146** (2), 191-197.

Lorenc-Koci, E., Wolfarth, S. und Ossowska, K. (1996)

Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity.
Exp Brain Res **109** (2), 268-276.

Lozano, A. M. und Mahant, N. (2004)

Deep brain stimulation surgery for Parkinson's disease: mechanisms and consequences.
Parkinsonism Relat Disord **10 Suppl 1** S49-57.

Lundblad, M., Picconi, B., Lindgren, H. und Cenci, M. A. (2004)

A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Neurobiol Dis **16** (1), 110-123.

- Lundblad, M., Usiello, A., Carta, M., Hakansson, K., Fisone, G. und Cenci, M. A. (2005)**
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Exp Neurol **194** (1), 66-75.
- Lykken, L. und Casida, J. E. (1969)**
Metabolism of organic insecticide chemicals.
Can Med Assoc J **100** (4), 145-154.
- Maharaj, H., Sukhdev Maharaj, D., Scheepers, M., Mokokong, R. und Daya, S. (2005)**
l-DOPA administration enhances 6-hydroxydopamine generation.
Brain Res **1063** (2), 180-186.
- Manczak, M., Jung, Y., Park, B. S., Partovi, D. und Reddy, P. H. (2005)**
Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging.
J Neurochem **92** (3), 494-504.
- Manfredi, M., Stocchi, F. und Vacca, L. (1995)**
Differential diagnosis of parkinsonism.
J Neural Transm Suppl **45** 1-9.
- Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L. und Di Monte, D. A. (2002)**
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein.
J Biol Chem **277** (3), 1641-1644.
- Marey-Semper, I., Gelman, M. und Levi-Strauss, M. (1995)**
A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation.
J Neurosci **15** (9), 5912-5918.
- Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S. und Herkenham, M. A. (1984)**
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.
Nature **311** (5985), 464-467.
- Marking, L. L. (1988)**
Oral Toxicity of Rotenone to Mammals.
In Survey, U. S. G. (ed.) *Investigations in Fish Control*.
- Marsden, C. D. und Obeso, J. A. (1994)**
The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease.
Brain **117** (Pt 4) 877-897.
- Martin, J. H. (1991)**
Autoradiographic estimation of the extent of reversible inactivation produced by microinjection of lidocaine and muscimol in the rat.
Neurosci Lett **127** (2), 160-164.
- Matthews, G. G. (2001)**
Neurobiology: molecules, cells, and systems.
Malden, Massachusetts, USA, Blackwell Science, Inc.,
- Maurice, T., Phan, V., Sandillon, F. und Urani, A. (2000)**
Differential effect of dehydroepiandrosterone and its steroid precursor pregnenolone against the behavioural deficits in CO-exposed mice.
Eur J Pharmacol **390** (1-2), 145-155.
- McCormack, A. L., Thiruchelvam, M., Thiffault, C., Langston, J. W., Cory-Slechta, D. A. und Di Monte, D. A. (2002)**
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Neurobiol Dis **10** (2), 119-127.
- McGeer, P. L., Itagaki, S., Akiyama, H. und McGeer, E. G. (1988a)**
Rate of cell death in parkinsonism indicates active neuropathological process.
Ann Neurol **24** (4), 574-576.
- McGeer, P. L., Itagaki, S., Boyes, B. E. und McGeer, E. G. (1988b)**
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains.
Neurology **38** (8), 1285-1291.

McIlwain, K. L., Merriweather, M. Y., Yuva-Paylor, L. A. und Paylor, R. (2001)

The use of behavioral test batteries: effects of training history.
Physiol Behav **73** (5), 705-717.

Meco, G., Bonifati, V., Vanacore, N. und Fabrizio, E. (1994)

Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate).
Scand J Work Environ Health **20** (4), 301-305.

Meissner, W., Hill, M. P., Tison, F., Gross, C. E. und Bezdard, E. (2004)

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.
Trends Pharmacol Sci **25** (5), 249-253.

Mellon, S. H. und Griffin, L. D. (2002)

Neurosteroids: biochemistry and clinical significance.
Trends Endocrinol Metab **13** (1), 35-43.

Metzger, R. R., Brown, J. M., Sandoval, V., Elwan, M. A., Miller, G. W., Hanson, G. R. und Fleckenstein, A. E. (2002)

Inhibitory effect of reserpine on dopamine transporter function.
Eur J Pharmacol **456** (1-3), 39-43.

Miller, R. M. und Federoff, H. J. (2005)

Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.
Neuroscientist **11** (6), 539-549.

Mink, J. W. (2003)

31. The Basal Ganglia.
In Squire, B., McConnell, Roberts, Spitzer, Zigmond (ed.): *Fundamental Neuroscience*.
London, Academic Press.

Mirzaei, H., Schieler, J. L., Rochet, J. C. und Regnier, F. (2006)

Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry.
Anal Chem **78** (7), 2422-2431.

Mitsumoto, Y., Watanabe, A., Mori, A. und Koga, N. (1998)

Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice.
Biochem Biophys Res Commun **248** (3), 660-663.

Mizuno, Y., Hattori, N. und Mori, H. (1999)

Genetics of Parkinson's disease.
Biomed Pharmacother **53** (3), 109-116.

Mizuno, Y., Mori, H. und Kondo, T. (1995)

Parkinson's disease: from etiology to treatment.
Intern Med **34** (11), 1045-1054.

Moore, R. Y., Bhatnagar, R. K. und Heller, A. (1971)

Anatomical and chemical studies of a nigro-neostriatal projection in the cat.
Brain Res **30** (1), 119-135.

Mori, H. und Mishina, M. (1995)

Structure and function of the NMDA receptor channel.
Neuropharmacology **34** (10), 1219-1237.

Morris, H. R. (2005)

Genetics of Parkinson's disease.
Ann Med **37** (2), 86-96.

Muralikrishnan, D. und Mohanakumar, K. P. (1998)

Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Faseb J **12** (10), 905-912.

Murphy, A. N., Fiskum, G. und Beal, M. F. (1999)

Mitochondria in neurodegeneration: bioenergetic function in cell life and death.
J Cereb Blood Flow Metab **19** (3), 231-245.

Nagatsu, T., Mogi, M., Ichinose, H. und Togari, A. (2000)

Cytokines in Parkinson's disease.
J Neural Transm Suppl (58), 143-151.

Negrette, B., Bonilla, E., Valero, N., Giraldoth, D., Medina-Leendertz, S. und Anez, F. (2001)

In mice the efficiency of immunization with Venezuelan Equine Encephalomyelitis virus TC-83 is transiently increased by dehydroepiandrosterone.
Invest Clin **42** (4), 235-240.

Nicklas, W. J., Vyas, I. und Heikkila, R. E. (1985)

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Life Sci **36** (26), 2503-2508.

Nobrega, J. N., Gernert, M., Loscher, W., Raymond, R., Belej, T. und Richter, A. (1999)

Tyrosine hydroxylase immunoreactivity and [³H]WIN 35,428 binding to the dopamine transporter in a hamster model of idiopathic paroxysmal dystonia.
Neuroscience **92** (1), 211-217.

Novelli, A., Reilly, J. A., Lysko, P. G. und Henneberry, R. C. (1988)

Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced.
Brain Res **451** (1-2), 205-212.

Nyholm, D. (2006)

Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Clin Pharmacokinet **45** (2), 109-136.

Obeso, J. A., Olanow, C. W. und Nutt, J. G. (2000)

Levodopa motor complications in Parkinson's disease.
Trends Neurosci **23** (10 Suppl), S2-7.

Olanow, C. W. und Jankovic, J. (2005)

Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Mov Disord **20** Suppl **11** S3-10.

Onn, S. P., Berger, T. W., Stricker, E. M. und Zigmond, M. J. (1986)

Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis.
Brain Res **376** (1), 8-19.

Orth, M. und Tabrizi, S. J. (2003)

Models of Parkinson's disease.
Mov Disord **18** (7), 729-737.

Parent, A. (1986)

Comparative Neurobiology of the Basal Ganglia.. New York, John Wiley & Sons

Parent, A. und Cicchetti, F. (1998)

The current model of basal ganglia organization under scrutiny.
Mov Disord **13** (2), 199-202.

Parent, A. und Hazrati, L. N. (1995)

Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop.
Brain Res Brain Res Rev **20** (1), 91-127.

Parker, W. D., Jr., Boyson, S. J. und Parks, J. K. (1989)

Abnormalities of the electron transport chain in idiopathic Parkinson's disease.
Ann Neurol **26** (6), 719-723.

Parkinson, J. (1817)

An essay on the shaking palsy.
Sherwood, Neely and Jones, London.

Paxinos, G. und Franklin, K. B. J. (2001)

The Mouse Brain in Stereotaxic Coordinates.
San Diego, Academic Press.

Paylor, R., Spencer, C. M., Yuva-Paylor, L. A. und Pieke-Dahl, S. (2006)

The use of behavioral test batteries, II: effect of test interval.
Physiol Behav **87** (1), 95-102.

Pearlson, G. D., Kubos, K. L. und Robinson, R. G. (1984)

Effect of anterior-posterior lesion location on the asymmetrical behavioral and biochemical response to cortical suction ablations in the rat.
Brain Res **293** (2), 241-250.

Perese, D. A., Ulman, J., Viola, J., Ewing, S. E. und Bankiewicz, K. S. (1989)

A 6-hydroxydopamine-induced selective parkinsonian rat model.
Brain Res **494** (2), 285-293.

Peretti-Renucci, R., Feuerstein, C., Manier, M., Lorimier, P., Thibault, J., Mons, N. und Geffard, M. (1991)

Quantitative image analysis with densitometry for immunohistochemistry and autoradiography of receptor binding sites--methodological considerations.
J Neurosci Res **28** (4), 583-600.

Perez, F. A., Curtis, W. R. und Palmiter, R. D. (2005)

Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity.
BMC Neurosci **6** 71.

Perier, C., Bove, J., Vila, M. und Przedborski, S. (2003)

The rotenone model of Parkinson's disease.
Trends Neurosci **26** (7), 345-346.

Perumal, A. S., Gopal, V. B., Tordzro, W. K., Cooper, T. B. und Cadet, J. L. (1992)

Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain.
Brain Res Bull **29** (5), 699-701.

Phinney, A. L., Andringa, G., Bol, J. G., Wolters, E., van Muiswinkel, F. L., van Dam, A. M. und Drukarch, B. (2006)

Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging.
Parkinsonism Relat Disord **12** (4), 228-238.

Pijlman, F. T., Wolterink, G. und Van Ree, J. M. (2003)

Physical and emotional stress have differential effects on preference for saccharine and open field behaviour in rats.
Behav Brain Res **139** (1-2), 131-138.

Platel, A. und Porsolt, R. D. (1982)

Habituation of exploratory activity in mice: a screening test for memory enhancing drugs.
Psychopharmacology (Berl) **78** (4), 346-352.

Poewe, W. und Luginger, E. (1999)

Depression in Parkinson's disease: impediments to recognition and treatment options.
Neurology **52** (7 Suppl 3), S2-6.

Pollack, A. E. (2001)

Anatomy, physiology, and pharmacology of the basal ganglia.
Neurol Clin **19** (3), 523-534, v.

Polymeropoulos, M. H., Lavedan, C., Leroy, E., G., Golbe, L. I. und Nussbaum, R. L. (1997)

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
Science **276** (5321), 2045-2047.

Przedborski, S. und Ischiropoulos, H. (2005)

Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease.
Antioxid Redox Signal **7** (5-6), 685-693.

Przedborski, S., Jackson-Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R. und Akram, M. (2001)

The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety.
J Neurochem **76** (5), 1265-1274.

Przedborski, S., Levivier, M., Jiang, H., Ferreira, M., Jackson-Lewis, V., Donaldson, D. und Togasaki, D. M. (1995)

Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
Neuroscience **67** (3), 631-647.

Rajput, A. H. (2001)

Levodopa prolongs life expectancy and is non-toxic to substantia nigra.
Parkinsonism Relat Disord **8** (2), 95-100.

Rego, A. C. und Oliveira, C. R. (2003)

Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases.
Neurochem Res **28** (10), 1563-1574.

Ren, Y., Zhao, J. und Feng, J. (2003)

Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation.
J Neurosci **23** (8), 3316-3324.

Ricaurte, G. A., DeLanney, L. E., Finnegan, K. T., Irwin, I. und Langston, J. W. (1988)

The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging.
Brain Res **438** (1-2), 395-398.

Richardson, J. R., Quan, Y., Sherer, T. B., Greenamyre, J. T. und Miller, G. W. (2005)

Paraquat Neurotoxicity is Distinct from that of MPTP and Rotenone.
Toxicol Sci.

Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K. und Youdim, M. B. (1989)

Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains.
J Neurochem **52** (2), 515-520.

Riederer, P. und Youdim, M. B. (1986)

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
J Neurochem **46** (5), 1359-1365.

Rinne, J. O., Rummukainen, J., Paljarvi, L. und Rinne, U. K. (1989)

Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra.
Ann Neurol **26** (1), 47-50.

Robinson, T. E. und Whishaw, I. Q. (1988)

Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats.
Brain Res **450** (1-2), 209-224.

Rock, R. B., Gekker, G., Hu, S., Sheng, W. S., Cheeran, M., Lokensgard, J. R. und Peterson, P. K. (2004)

Role of microglia in central nervous system infections.
Clin Microbiol Rev **17** (4), 942-964, table of contents.

Roedter, A., Winkler, C., Samii, M., Walter, G. F., Brandis, A. und Nikkhah, G. (2001)

Comparison of unilateral and bilateral intrastratial 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways.
J Comp Neurol **432** (2), 217-229.

Romeis, B. (1989)

Mikroskopische Technik. München, Urban und Schwarzenberg.

Rothblat, D. S., Schroeder, J. A. und Schneider, J. S. (2001)

Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism.
J Neurosci Res **65** (3), 254-266.

Rozas, G., Lopez-Martin, E., Guerra, M. J. und Labandeira-Garcia, J. L. (1998)

The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
J Neurosci Methods **83** (2), 165-175.

Sachs, C. und Jonsson, G. (1975)

Mechanisms of action of 6-hydroxydopamine.
Biochem Pharmacol **24** (1), 1-8.

Saint-Pierre, M., Tremblay, M. E., Sik, A., Gross, R. E. und Cicchetti, F. (2006)

Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats.
J Neurochem **98** (3), 760-772.

Sanberg, P. R. (1980)

Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors.
Nature **284** (5755), 472-473.

Sanberg PR, Martinez R, Shytle RD und DW., C. (1996)

The Catalepsy Test.
In Sanberg, P., Ossenkopp, K.-P. und Kavaliers, M. (eds.): Motor Activity and Movement Disorders.
Totowa, Humana Press, 197-211.

Sanberg, P. R., Bunsey, M. D., Giordano, M. und Norman, A. B. (1988)

The catalepsy test: its ups and downs.
Behav Neurosci **102** (5), 748-759.

Sander, S. E., Hamann, M. und Richter, A. (2006)

Age-related changes in striatal nitric oxide synthase-immunoreactive interneurons in the dystonic dtz mutant hamster.
Neuropathol Appl Neurobiol **32** (1), 74-82.

Sander, S. E. und Richter, A. (2006)

Striatal microinjections of nitric oxide synthase inhibitors and l-arginine fail to exert effects on paroxysmal dystonia in the dt(sz) mutant.
Neurosci Lett.

Sandoe, P. (1994)

Animal Research and Ethics.
In Svendsen, P. a. H., J. (ed.): *Handbook of Laboratory Animal Science*.
Boca Raton, Florida, USA, CRC Press LLC.

Sawle, G. V., Colebatch, J. G., Shah, A., Brooks, D. J., Marsden, C. D. und Frackowiak, R. S. (1990)

Striatal function in normal aging: implications for Parkinson's disease.
Ann Neurol **28** (6), 799-804.

Schapira, A. H. (1999)

Science, medicine, and the future: Parkinson's disease.
Bmj **318** (7179), 311-314.

Schapira, A. H. (2005)

Present and future drug treatment for Parkinson's disease.
J Neurol Neurosurg Psychiatry **76** (11), 1472-1478.

Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P. und Marsden, C. D. (1990)

Mitochondrial complex I deficiency in Parkinson's disease.
J Neurochem **54** (3), 823-827.

Schneider, J. A., Bienias, J. L., Gilley, D. W., Kvarnberg, D. E., Mufson, E. J. und Bennett, D. A. (2002)

Improved detection of substantia nigra pathology in Alzheimer's disease.
J Histochem Cytochem **50** (1), 99-106.

Schober, A. (2004)

Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
Cell Tissue Res **318** (1), 215-224.

Schuler, F. und Casida, J. E. (2001)

Functional coupling of PSST and ND1 subunits in NADH:ubiquinone oxidoreductase established by photoaffinity labeling.
Biochim Biophys Acta **1506** (1), 79-87.

Schwartz, R. K. und Huston, J. P. (1996a)

The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.
Prog Neurobiol **50** (2-3), 275-331.

Schwartz, R. K. und Huston, J. P. (1996b)

Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae.
Prog Neurobiol **49** (3), 215-266.

Scott, W. K., Nance, M. A., Watts, R. L., Hubble, J. P., Vance, J. M. und Pericak-Vance, M. A. (2001)

Complete genomic screen in Parkinson disease: evidence for multiple genes.
Jama **286** (18), 2239-2244.

Sedelis, M., Hofele, K., Auburger, G. W., Morgan, S., Huston, J. P. und Schwartz, R. K. (2000)

MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences.
Behav Genet **30** (3), 171-182.

Sedelis, M., Schwartz, R. K. und Huston, J. P. (2001)

Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
Behav Brain Res **125** (1-2), 109-125.

Seiden, L. S. und Vosmer, G. (1984)

Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine.
Pharmacol Biochem Behav **21** (1), 29-31.

- Seidler, A., Hellenbrand, W., Robra, B. P., Vieregge, P., Nischan, P., Oertel, W. H., Ulm, G. und Schneider, E. (1996)**
Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany.
Neurology **46** (5), 1275-1284.
- Semchuk, K. M., Love, E. J. und Lee, R. G. (1992)**
Parkinson's disease and exposure to agricultural work and pesticide chemicals.
Neurology **42** (7), 1328-1335.
- Seniuk, N. A., Tatton, W. G. und Greenwood, C. E. (1990)**
Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP.
Brain Res **527** (1), 7-20.
- Sershen, H., Hashim, A. und Lajtha, A. (1987)**
Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
Pharmacol Biochem Behav **28** (2), 299-303.
- Shaw, K. M., Lees, A. J. und Stern, G. M. (1980)**
The impact of treatment with levodopa on Parkinson's disease.
Q J Med **49** (195), 283-293.
- Sherer, T. B., Betarbet, R. und Greenamyre, J. T. (2001a)**
Pathogenesis of Parkinson's disease.
Curr Opin Investig Drugs **2** (5), 657-662.
- Sherer, T. B., Betarbet, R. und Greenamyre, J. T. (2001b)**
Pesticides and Parkinson's disease.
ScientificWorldJournal **1** 207-208.
- Sherer, T. B., Betarbet, R., Kim, J. H. und Greenamyre, J. T. (2003a)**
Selective microglial activation in the rat rotenone model of Parkinson's disease.
Neurosci Lett **341** (2), 87-90.
- Sherer, T. B., Betarbet, R., Stout, A. K., Lund, S., Baptista, M., Cookson, M. R. und Greenamyre, J. T. (2002)**
An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
J Neurosci **22** (16), 7006-7015.
- Sherer, T. B., Betarbet, R., Testa, C. M., Seo, B. B., Kim, G. W., Matsuno-Yagi, A. und Greenamyre, J. T. (2003b)**
Mechanism of toxicity in rotenone models of Parkinson's disease.
J Neurosci **23** (34), 10756-10764.
- Sherer, T. B. und Greenamyre, J. T. (2005)**
Oxidative damage in Parkinson's disease.
Antioxid Redox Signal **7** (5-6), 627-629.
- Sherer, T. B., Kim, J. H., Betarbet, R. und Greenamyre, J. T. (2003c)**
Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
Exp Neurol **179** (1), 9-16.
- Sherer, T. B., Trimmer, P. A., Borland, K., Parks, J. K., Bennett, J. P., Jr. und Tuttle, J. B. (2001c)**
Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells.
Brain Res **891** (1-2), 94-105.
- Shimizu, K., Ohtaki, K., Matsubara, K., Aoyama, K., Uezono, T., Hayase, N., Kimura, K. und Shiono, H. (2001)**
Carrier-mediated processes in blood--brain barrier penetration and neural uptake of paraquat.
Brain Res **906** (1-2), 135-142.
- Sian, J., Gerlach, M., Youdim, M. B. und Riederer, P. (1999)**
Parkinson's disease: a major hypokinetic basal ganglia disorder.
J Neural Transm **106** (5-6), 443-476.
- Sibley, D. R. und Monsma, F. J., Jr. (1992)**
Molecular biology of dopamine receptors.
Trends Pharmacol Sci **13** (2), 61-69.
- Skrinjaric-Spoljar, M., Matthews, H. B., Engel, J. L. und Casida, J. E. (1971)**
Response of hepatic microsomal mixed-function oxidases to various types of insecticide chemical synergists administered to mice.
Biochem Pharmacol **20** (7), 1607-1618.

Snyder, A. M., Stricker, E. M. und Zigmond, M. J. (1985)

Stress-induced neurological impairments in an animal model of parkinsonism.
Ann Neurol **18** (5), 544-551.

Snyder, G. L., Keller, R. W., Jr. und Zigmond, M. J. (1990)

Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals.
J Pharmacol Exp Ther **253** (2), 867-876.

Sotnikova, T. D., Beaulieu, J. M., Gainetdinov, R. R. und Caron, M. G. (2006)

Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter.
CNS Neurol Disord Drug Targets **5** (1), 45-56.

Spencer, J. P., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C. und Halliwell, B. (1998)

Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
J Neurochem **71** (5), 2112-2122.

Stromberg, I., Bjorklund, H., Dahl, D., Jonsson, G., Sundstrom, E. und Olson, L. (1986)

Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry.
Brain Res Bull **17** (2), 225-236.

Sundstrom, E., Fredriksson, A. und Archer, T. (1990)

Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Brain Res **528** (2), 181-188.

Sved, A. F., Baker, H. A. und Reis, D. J. (1984)

Dopamine synthesis in inbred mouse strains which differ in numbers of dopamine neurons.
Brain Res **303** (2), 261-266.

Takahashi, R., Imai, Y., Hattori, N. und Mizuno, Y. (2003)

Parkin and endoplasmic reticulum stress.
Ann N Y Acad Sci **991** 101-106.

Talpade, D. J., Greene, J. G., Higgins, D. S., Jr. und Greenamyre, J. T. (2000)

In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone.
J Neurochem **75** (6), 2611-2621.

Tanila, H., Bjorklund, M. und Riekkinen, P., Jr. (1998)

Cognitive changes in mice following moderate MPTP exposure.
Brain Res Bull **45** (6), 577-582.

Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. und Langston, J. W. (1999)

Parkinson disease in twins: an etiologic study.
Jama **281** (4), 341-346.

Tawara, T., Fukushima, T., Hojo, N., Isobe, A., Shiwaku, K., Setogawa, T. und Yamane, Y. (1996)

Effects of paraquat on mitochondrial electron transport system and catecholamine contents in rat brain.
Arch Toxicol **70** (9), 585-589.

Testa, C. M., Sherer, T. B. und Greenamyre, J. T. (2005)

Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Brain Res Mol Brain Res **134** (1), 109-118.

Thiffault, C., Langston, J. W. und Di Monte, D. A. (2000)

Increased striatal dopamine turnover following acute administration of rotenone to mice.
Brain Res **885** (2), 283-288.

Thiruchelvam, M., McCormack, A., Richfield, E. K., Tank, A. W., Di Monte, D. A. und Cory-Slechta, D. A. (2003)

Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype.
Eur J Neurosci **18** (3), 589-600.

Thiruchelvam, M., Richfield, E. K., Baggs, R. B., Tank, A. W. und Cory-Slechta, D. A. (2000)

The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease.
J Neurosci **20** (24), 9207-9214.

Thoenen, H. und Tranzer, J. P. (1973)

The pharmacology of 6-hydroxydopamine.
Annu Rev Pharmacol **13** 169-180.

Thomas, A., Iacono, D., Luciano, A. L., Armellino, K., Di Iorio, A. und Onofrj, M. (2004)

Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
J Neurol Neurosurg Psychiatry **75** (1), 141-143.

Thompson, C. B. (1995)

Apoptosis in the pathogenesis and treatment of disease.
Science **267** (5203), 1456-1462.

Tolosa, E., Wenning, G. und Poewe, W. (2006)

The diagnosis of Parkinson's disease.
Lancet Neurol **5** (1), 75-86.

Tretiakoff, C. (1919)

Contribution a l'etude de l'anatomie pathologique du locus niger de Soemmering avec quelques deductions relatives a la pathogenie des troubles du tonus musculaire et de la maladie de Parkinson. .
These de Paris.

Twelves, D., Perkins, K. S. und Counsell, C. (2003)

Systematic review of incidence studies of Parkinson's disease.
Mov Disord **18** (1), 19-31.

Ungerstedt, U. (1968)

6-Hydroxy-dopamine induced degeneration of central monoamine neurons.
Eur J Pharmacol **5** (1), 107-110.

Uversky, V. N. (2004)

Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration.
Cell Tissue Res **318** (1), 225-241.

Van Zutphen, L. F. M., Baumans, V. und Beynen, A. C. (1995)

Grundlagen der Versuchstierkunde. Stuttgart, Enke, Fischer (Gustav),

Vanacore, N., Nappo, A., Gentile, M., Brustolin, A., Palange, S., Bonifati, V., Quercia, A. und Meco, G. (2002)

Evaluation of risk of Parkinson's disease in a cohort of licensed pesticide users.
Neurol Sci **23 Suppl 2** S119-120.

Vieregge, P. (1994)

Genetic factors in the etiology of idiopathic Parkinson's disease.
J Neural Transm Park Dis Dement Sect **8** (1-2), 1-37.

Vitek, J. L. (2002)

Pathophysiology of dystonia: a neuronal model.
Mov Disord **17 Suppl 3** S49-62.

von Bohlen und Halbach, O., Schober, A. und Krieglstein, K. (2004)

Genes, proteins, and neurotoxins involved in Parkinson's disease.
Prog Neurobiol **73** (3), 151-177.

Von Voigtlander, P. F. und Moore, K. E. (1973)

Turning behavior of mice with unilateral 6-hydroxydopamine lesions in the striatum: effects of apomorphine, L-DOPA, amantadine, amphetamine and other psychomotor stimulants.
Neuropharmacology **12** (5), 451-462.

Votyakova, T. V. und Reynolds, I. J. (2005)

Ca²⁺-induced permeabilization promotes free radical release from rat brain mitochondria with partially inhibited complex I.
J Neurochem **93** (3), 526-537.

Wager-Smith, K. und Kay, S. A. (2000)

Circadian rhythm genetics: from flies to mice to humans.
Nat Genet **26** (1), 23-27.

Wahlsten, D., Metten, P., Phillips, T. J., Boehm, S. L., Wenger, C. D., Dudek, B. C. und Crabbe, J. C. (2003)

Different data from different labs: lessons from studies of gene-environment interaction.
J Neurobiol **54** (1), 283-311.

Wang, X., Chen, S., Ma, G., Ye, M. und Lu, G. (2005)

Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca²⁺ disturbance in microglia activation-mediated dopaminergic cell degeneration.
Mech Ageing Dev **126** (12), 1241-1254.

Weihmuller, F. B., Hadjiconstantinou, M. und Bruno, J. P. (1988)

Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice.
Neurosci Lett **85** (1), 137-142.

Willner, P. (1986)

Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case.
Prog Neuropsychopharmacol Biol Psychiatry **10** (6), 677-690.

Yakovlev, A. G. und Faden, A. I. (2004)

Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies.
NeuroRx **1** (1), 5-16.

Yang, M. C., McLean, A. J. und Le Couteur, D. G. (2002)

Age-related alteration in hepatic disposition of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pesticides.
Pharmacol Toxicol **90** (4), 203-207.

Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R. und Mizuno, Y. (1996)

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Proc Natl Acad Sci U S A **93** (7), 2696-2701.

Youdim, M. B., Ben-Shachar, D. und Riederer, P. (1994)

The enigma of neuromelanin in Parkinson's disease substantia nigra.
J Neural Transm Suppl **43** 113-122.

Zecca, L., Gallorini, M., Schunemann, V., Gerlach, M., Riederer, P., Vezzoni, P. und Tampellini, D. (2001)

Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes.
J Neurochem **76** (6), 1766-1773.

Zecca, L., Zucca, F. A., Costi, P., Tampellini, D., Riederer, P., Ito, S., Gallorini, M. und Sulzer, D. (2003)

The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour.
J Neural Transm Suppl (65), 145-155.

Zeevalk, G. D. und Bernard, L. P. (2005)

Energy status, ubiquitin proteasomal function, and oxidative stress during chronic and acute complex I inhibition with rotenone in mesencephalic cultures.
Antioxid Redox Signal **7** (5-6), 662-672.

Zhang, Z. X. und Roman, G. C. (1993)

Worldwide occurrence of Parkinson's disease: an updated review.
Neuroepidemiology **12** (4), 195-208.

Zhu, C., Vour'h, P., Fernagut, P. O., Fleming, S. M., Lacan, S., Seaman, R. L. und Chesselet, M. F. (2004)

Variable effects of chronic subcutaneous administration of rotenone on striatal histology.
J Comp Neurol **478** (4), 418-426.

Zigmond, M. J. und Stricker, E. M. (1984)

Parkinson's disease: studies with an animal model.
Life Sci **35** (1), 5-18.

Ziv, I. und Melamed, E. (1998)

Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity?
Mov Disord **13** (6), 865-870.

Ziv, I., Melamed, E., Nardi, N., Luria, D., Achiron, A., Offen, D. und Barzilai, A. (1994)

Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease.
Neurosci Lett **170** (1), 136-140.

Zoccarato, F., Toscano, P. und Alexandre, A. (2005)

Dopamine-derived dopaminochrome promotes H₂O₂ release at mitochondrial complex I: stimulation by rotenone, control by Ca²⁺, and relevance to Parkinson disease.
J Biol Chem **280** (16), 15587-15594.